The announcement of a substantial cash reserve and financial assets for ProQR Therapeutics suggests a reduced risk of near-term financial distress, potentially leading to increased investor confidence. This financial stability is crucial for a biotech company, as it ensures the continuation of research and development activities without the immediate need for additional fundraising, which could dilute existing shares. Therefore, this news is likely to have a positive impact on PRQR's stock price in the short term.